TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18487565
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with carboplatin (AUC, 6) and paclitaxel (225 mg/m(2)); followed by weekly carboplatin (AUC, 2) and paclitaxel (45 mg/m(2)) with 74 Gy of TRT
Study: 18487565
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with carboplatin (AUC, 5) and gemcitabine (1,000 mg/m(2)); followed by biweekly gemcitabine (35 mg/m(2)) with 74 Gy of TRT
Study: 12708902
Drug: Clivarin (low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clivarin (low-molecular-weight heparin) administered subcutaneously at a fixed daily dosage of 1750 U
Study: 4029877
Drug: 150 microgram
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 microgram of L-thyroxine
Study: 24578449
Drug: Perioperative glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative glutamine administration
Study: 14578687
Drug: Bryostatin-1 25
Normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryostatin-1 25 microg/m2 as a 1h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I)
Study: 14578687
Drug: Bryostatin-1 120
Normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryostatin-1 120 microg/m2 as a 72 h continuous infusion every 2 weeks (Regimen II)
Study: 8103770
Drug: Pyridostigmine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (120 mg, orally, at -60 min) plus GHRH (1 microgram/kg, iv, at 0 min)
Study: 8103770
Drug: Arginine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine (30 g, iv, from 0-30 min) plus GHRH (1 microgram/kg, iv, at 0 min)
Study: 29518230
Drug: Mindfulness for
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness for Pain and Performance Enhancement (MPPE) - Acceptance and Commitment Therapy-based program; six sessions over 2 weeks.
Study: 29518230
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment services (control group); physical therapy, medical interventions, and psychoeducational groups.
Study: 27542236
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU vitamin D and 1000 mg calcium/day (tablet group)
Study: 22954508
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (doxorubicin 75 mg/m², ifosfamide 5 g/m², lenograstim)
Study: 22954508
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (doxorubicin, ifosfamide)
Study: 20384716
Drug: Study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug (new antiepileptic drugs)
Study: 19025610
Drug: Sublingual sugar
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual sugar (SLS)
Study: 19025610
Drug: Intravenous 10%
Normalized name: fat emulsion, intravenous 10% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 10% glucose (IVG)
Study: 15858602
Drug: L-carnitine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (50 mumol/kg/day, intravenously until infants tolerated 16 ml/day of feeds)
Study: 14634414
Drug: Apomorphine hydrochloride
Normalized name: Apomorphine Hydrochloride
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine hydrochloride 2 mg
Study: 14634414
Drug: Apomorphine hydrochloride
Normalized name: Apomorphine Hydrochloride
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine hydrochloride 3 mg
Study: 14634414
Drug: Apomorphine hydrochloride
Normalized name: Apomorphine Hydrochloride
DrugBank: Apomorphine (DB00714)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apomorphine hydrochloride (dose increased from 2 to 3 mg)
Study: 10463681
Drug: Japanese encephalitis
Normalized name: Japanese Encephalitis IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese encephalitis vaccine (inactivated, BIKEN), administered in two dosing regimens (days 0, 7, and either 14 or 30)
Study: 10463681
Drug: Japanese encephalitis
Normalized name: Japanese Encephalitis IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese encephalitis vaccine (inactivated, BIKEN)
Study: 8020876
Drug: Platelet-aggregation factor
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-aggregation factor inhibitor (single doses)
Study: 16808776
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of medical or psychosocial contraindications to outpatient treatment
Study: 16808776
Drug: Home therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home therapy with oxygen, corticosteroids, or antibiotics before presentation
Study: 16808776
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of one or more contraindications to outpatient treatment
Study: 16808776
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of low-risk patients in the outpatient setting
Study: 12774577
Drug: Five-bevel needle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-bevel needle for subcutaneous administration
Study: 11045835
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no cutaneous treatment)
Study: 3304412
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg methylprednisolone (Solumedrone Upjohn Limited) given intravenously immediately preoperatively
Study: 23103430
Drug: Group singing
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group singing training 3 times weekly for 12 weeks
Study: 18416072
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of acupuncture and Chinese medicines
Study: 17021267
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation (PO)
Study: 8872691
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil (10 micrograms) followed by 12 ml of saline
Study: 8872691
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine (12 ml of 0.25% bupivacaine)
Study: 6288627
Drug: Guar (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar (5 or 10 g) in aqueous solution
Study: 6288627
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (any dosage)
Study: 30259703
Drug: AX (astaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AX (astaxanthin 12 mg, tocotrienol 10 mg, zinc 6 mg)
Study: 26843086
Drug: MEDI4212 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4212 (subcutaneous doses of 5, 15, 60, 150, or 300 mg; intravenous dose of 300 mg)
Study: 26843086
Drug: Omalizumab (subcutaneous)
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab (subcutaneous)
Study: 21593352
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g l-glutamine (Gln-30)
Study: 21593352
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g L-glutamine (Gln-15)
Study: 21593352
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg SIT
Study: 21593352
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg SIT and 15 g L-glutamine (SIT+Gln-15)
Study: 19920419
Drug: T2 thermolesion
Approvals — FDA: no, EMA: no, PMDA: no
Description: T2 thermolesion with local application of 0.5 mL of 6% phenol
Study: 16834836
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg for 8 weeks
Study: 16834836
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg for 12 weeks (controlled patients)
Study: 15323064
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg/day
Study: 16834836
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg/day or olmesartan 20 mg/day plus 12.5 mg hydrochlorothiazide for 4 weeks (non-controlled patients)
Study: 8874573
Drug: Intraarticular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular morphine 5 mg
Study: 9088813
Drug: Intraarticular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular morphine 1 mg
Study: 9088813
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 20 mL (Control)
Study: 21753777
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (twice a week for 6 months, emphasizing swimming)
Study: 20110025
Drug: SAMe 1200
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMe 1200 mg/d (400 mg TID)
Study: 20110025
Drug: Nabumetone 1000
Normalized name: nabumetone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone 1000 mg/d (once daily in the evening)
Study: 8339409
Drug: Warfarin prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin prophylaxis (adjusted to prolong INR to 1.5 on the day of surgery and 2.5 after surgery)
Study: 24996842
Drug: Synbiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic therapy for 6 weeks
Study: 20038863
Drug: Standard Early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Early Treatment Diabetic Retinopathy Study focal laser treatment
Study: 16580904
Drug: Voriconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voriconazole (400 mg twice daily on the first day and 200 mg twice daily on the second day)
Study: 9296215
Drug: Molgramostim 5
Normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molgramostim 5 micrograms/kg every 12 hours for 14 days, given alongside chemotherapy regimens.
Study: 30606383
Drug: CT angiography
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT angiography using low-voltage (80 kVp) and low-concentration contrast media (300 mgI/ml) with IMR algorithm
Study: 30606383
Drug: CT angiography
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT angiography using regular voltage (100 kVp) and higher concentration contrast media (370 mgI/ml) with hybrid iterative reconstruction technique
Study: 26907736
Drug: Ledipasvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily plus ribavirin (600‐1200 mg daily) for 12 weeks
Study: 26907736
Drug: Ledipasvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) once daily plus ribavirin (600‐1200 mg daily) for 24 weeks
Study: 18366766
Drug: Open-label continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label continuous combined hormone therapy
Study: 15604942
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with monitoring using (99m)Tc-Sestamibi scintimammography
Study: 6633596
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of progesterone receptors
Study: 6633596
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of estrogen receptors
Study: 6633596
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of estrogen and progesterone receptors
Study: 29126981
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 1200 mg
Study: 26857782
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg ropivacaine plus 5 μg dexmedetomidine (RD)
Study: 26857782
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg ropivacaine plus 15 μg fentanyl (RF)
Study: 26857782
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg ropivacaine (R)
Study: 19153116
Drug: FOLFIRI-3 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI-3 (irinotecan 100 mg/m(2) days 1 and 3 combined with LV 400 mg/m(2) day 1 and 46-h continuous 5-FU 2000 mg/m(2))
Study: 19153116
Drug: FOLFIRI-1 (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI-1 (irinotecan 180 mg/m(2) day 1 combined with LV 400 mg/m(2) day 1, 5-FU bolus 400 mg/m(2) and 46-h continuous 5-FU 2400 mg/m(2))
Study: 15182413
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day antibiotic prophylaxis (ciprofloxacin or levofloxacin)
Study: 15182413
Drug: 3 day
Normalized name: Kathro 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 day antibiotic prophylaxis (ciprofloxacin or levofloxacin)
Study: 15182413
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day antibiotic prophylaxis
Study: 15182413
Drug: 3 day
Normalized name: Kathro 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 day antibiotic prophylaxis
Study: 12201823
Drug: Non-GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-GH treatment
Study: 9812183
Drug: High-dose standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose standard heparin 300 U/kg as an intravenous bolus
Study: 2693117
Drug: 4-methylpyrazole (4‐MP)
Normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-methylpyrazole (4‐MP) at 10 mg.kg‐1
Study: 2693117
Drug: 4-methylpyrazole (4‐MP)
Normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-methylpyrazole (4‐MP) at 20 mg.kg‐1
Study: 2693117
Drug: 4-methylpyrazole (4‐MP)
Normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-methylpyrazole (4‐MP) at 100 mg.kg‐1
Study: 28651249
Drug: TRO40303 (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRO40303 (intravenous bolus)
Study: 25604090
Drug: Social media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social media intervention for low-income adolescent mothers; delivered via a web-based application over 6 weeks, includes daily behavioral challenges, text message reminders, discussion forums, and website information.
Study: 19543563
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to a dual reuptake inhibitor
Study: 19543563
Drug: Augmentation strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation strategies
Study: 19543563
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy as a switch or augmentation strategy
Study: 19543563
Drug: Antidepressants in
Normalized name: Other antidepressants in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants in augmentation
Study: 17465354
Drug: Ulna implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulna implants with surrounding bone blocks
Study: 17465354
Drug: Conventional sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sinus augmentation with particulated autogenous bone grafts
Study: 15649285
Drug: ISO (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISO (100 mg) tablets
Study: 15649285
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (P group) containing vitamins C (25 mg) and E (5 mg)
Study: 9533351
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical treatment with oral agents and exogenous insulin injection
Study: 3391875
Drug: Erythromycin acistrate
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin acistrate (EA) 400 mg
Study: 3391875
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (EB) enterotablet A 500 mg
Study: 3391875
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (EB) enterotablet B 500 mg
Study: 3391875
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (EB) enterotablet A 500 mg (multiple dosing)
Study: 3391875
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (EB) enterotablet B 500 mg (multiple dosing)
Study: 3391875
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 + 800 mg
Study: 29363287
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg twice daily (LOR BID)
Study: 29363287
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg twice daily (LOR BID) + Phentermine 15 mg once daily (LOR BID + PHEN QD)
Study: 29363287
Drug: Lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin 10 mg twice daily (LOR BID) + Phentermine 15 mg twice daily (LOR BID + PHEN BID)
Study: 27353237
Drug: Temporary, transcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporary, transcutaneous, pharmaceutical SGB with lidocaine
Study: 17825472
Drug: Skin closure
Normalized name: dressings, skin closures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin closure by staples with closure of subcutaneous space
Study: 17825472
Drug: Skin closure
Normalized name: dressings, skin closures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin closure by staples with non-closure of subcutaneous space
Study: 17825472
Drug: Intracutaneous suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous suture with closure of subcutaneous space
Study: 17825472
Drug: Intracutaneous suture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous suture with non-closure of subcutaneous space
Study: 16389216
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (18, 36, 54, or 72 mg once daily)
Study: 12930332
Drug: High-power 50-ms
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-power 50-ms 1064 Nd:YAG laser treatment
Study: 11293738
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mcg/kg) administered intravenously within 1 hour of surgery and every 12 hours thereafter, switched to enteral captopril (3 mg/kg/day) every 8 hours when tolerating feeds.
Study: 11293738
Drug: No angiotensin
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No angiotensin converting enzyme inhibitors administered (Control group).
Study: 8433561
Drug: Insulin with
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin with dextrose infusion
Study: 8433561
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion with insulin and glucose
Study: 3303247
Drug: Non-administered group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-administered group
Study: 30479287
Drug: Anesthetic cream
Normalized name: DIBUCAINE/DIPERODON ANESTHETIC CREAM
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetic cream (2.5% lidocaine/2.5% prilocaine)
Study: 27683967
Drug: Interpersonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal therapy for complicated grief (CG) treatment
Study: 26577943
Drug: Home group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home group (oral amoxicillin treatment at home)
Study: 26577943
Drug: Hospital group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital group (oral amoxicillin treatment in hospital for first 48 hours)
Study: 19034749
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 to 120 mg QD, titrated based on response, with 90 mg QD as an intermediate dose)
Study: 12667566
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy after VT
Study: 12667566
Drug: ICD therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD therapy after VF
Study: 11108507
Drug: Anticonvulsant levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticonvulsant levels
Study: 9183334
Drug: rt-PA and
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rt-PA and heparin therapy
Study: 30007160
Drug: Guanfacine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 0.1 mg
Study: 7669311
Drug: Guanfacine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine 0.5 mg
Study: 30007160
Drug: Guanfacine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (both doses)
Study: 22573644
Drug: Diet plus
Normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet plus pravastatin (10-20 mg/d)